Valuation : Glaukos Corporation

Market Cap 10.65B 9.14B 8.58B 7.83B 14.78B 1,015B 14.85B 101B 39.33B 512B 39.97B 39.1B 1,697B P/E 2026 *
-223x
P/E 2027 * 615x
Enterprise Value 10.47B 8.99B 8.44B 7.7B 14.54B 999B 14.61B 99.83B 38.69B 504B 39.31B 38.46B 1,669B EV / Sales 2026 *
15.2x
EV / Sales 2027 * 12.3x
Free-Float
96.35%
Yield 2026 *
-
Yield 2027 * -
1 day-0.45%
1 week-4.74%
Current month+8.31%
1 month+17.57%
3 months+57.06%
6 months+48.70%
Current year+59.92%
1 week 176.82
Extreme 176.82
187.6
1 month 145.78
Extreme 145.7759
191.62
Current year 93.96
Extreme 93.96
191.62
1 year 73.16
Extreme 73.16
191.62
3 years 59.22
Extreme 59.22
191.62
5 years 33.33
Extreme 33.33
191.62
10 years 23.08
Extreme 23.075
191.62
Manager TitleAgeSince
Chief Executive Officer 65 01/01/2001
Director of Finance/CFO 56 01/04/2022
President 50 01/04/2022
Director TitleAgeSince
Chairman 65 31/12/2021
Director/Board Member 71 01/07/2014
Director/Board Member 57 01/07/2014
Date Insider Type Main position Quantity % Market Cap.
19/08/26 Fiscal year

Director

7,500 0.0131%
11/08/26 Fiscal year

Chairperson

180,000 0.3139%
07/08/26 Fiscal year

Chief Financial Officer

60,000 0.1046%
Change 5-day change 1-year change 3-year change Capi.($)
-0.45%-4.74%+92.53%+144.41% 10.65B
-0.28%-3.03%-16.40%+18.54% 126B
-0.47%-0.33%-22.83%-0.75% 12.24B
+2.13%-4.21%-51.63%-68.92% 4.21B
+0.57%+4.02%-22.01%+58.76% 2.77B
+1.20%+0.18%-32.64%-71.33% 1.79B
+1.12%-0.84%-23.32%-12.99% 1.66B
+0.47%-3.59%-36.96%-38.68% 1.59B
-1.29%-4.72%-18.99%-54.97% 1.46B
Average +0.33%-1.04%-14.70%-2.88% 18.09B
Weighted average by Cap. -0.20%-2.64%-11.24%+21.22%

Financials

2026 *2027 *
Net sales 691M 593M 557M 508M 959M 65.89B 964M 6.59B 2.55B 33.24B 2.59B 2.54B 110B 845M 725M 680M 621M 1.17B 80.55B 1.18B 8.05B 3.12B 40.64B 3.17B 3.1B 135B
Net income -51.88M -44.53M -41.8M -38.17M -72.04M -4.95B -72.39M -495M -192M -2.5B -195M -191M -8.27B 18.93M 16.24M 15.25M 13.93M 26.28M 1.81B 26.41M 180M 69.93M 911M 71.06M 69.52M 3.02B
Net Debt -175M -150M -141M -129M -243M -16.68B -244M -1.67B -646M -8.41B -657M -642M -27.87B -273M -234M -220M -201M -379M -26.02B -381M -2.6B -1.01B -13.13B -1.02B -1B -43.48B
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
26/08/26 $180.57 -0.45% 506,040
25/08/26 $181.39 -2.29% 639,693
24/08/26 $185.65 +0.41% 622,292
21/08/26 $184.89 0.00% 440,096
20/08/26 $184.89 -2.46% 791,869
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
180.57USD
Average target price
197.15USD
Spread / Average Target
+9.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GKOS Stock